The Treatment of Amoebic Dysentery S

Total Page:16

File Type:pdf, Size:1020Kb

The Treatment of Amoebic Dysentery S 638 Postgrad Med J: first published as 10.1136/pgmj.36.420.638 on 1 October 1960. Downloaded from THE TREATMENT OF AMOEBIC DYSENTERY S. BELL, M.D., M.R.C.P.(EDIN.), D.T.M. & H. Department of Clinical Tropical Medicine, Hospitalfor Tropical Diseases, London, N.W.i Diagnosis of infection with Entamoeba histolytica Recent Advances in Drug Therapy remains the most important practical problem, The groups of drugs available for the treatment and is the essential pre-requisite for effective of intestinal amoebiasis are: treatment. Without reliable parasitological diag- (I) Emetine and its compounds especially nosis follow-up examinations are virtually useless, emetine bismuth iodide. and attempts to assess the curative value of courses (2) Iodoquinoline compounds such as di- of treatment are worthless. In many tropical and hydroxy-iodoquinoline (Yatren, Chiniofon, sub-tropical areas carriers of the cystic form of the Enterovioform, etc.). parasite are so numerous that, until very recently, (3) Organic arsenicals such as Carbasone. radical treatment of them was outside the bounds (4) Antibiotics. ofpossibility. Thus the main effort there has been (5) Synthetic compounds and others, e.g.Protected by copyright. directed to treatment of the patient suffering from Camoform, Glaucarubin, compounds of amoebic dysentery or one of its complications. dichloroacet - 4- hydroxy - n - methylanilide (Entamide). Status of the Parasite Fundamental research both on the amoebic Acute Amoebic Dysentery parasite and on the host parasite relation is of The drug of choice to relieve acute symptoms is great importance, for knowledge is incomplete emetine hydrochloride i gr. daily (6o mg.) by about the pathogenicity of various strains of the subcutaneous injection for four to seven days. organism, and about the factors which may This drug alone, however, even in a longer course, precipitate acute amoebic dysentery and hepatic does not result in a high radical cure rate. By abscess or which cause the parasite to remain in the using it to control the acute symptoms and then cystic stage as a latent infection. changing to oral administration of emetine bis- Hoare2 has attempted to clarify the nomenclature muth iodide (EBI) a much better cure rate can of the large and small race parasites. The small be achieved. EBI should be dispensed in freshhttp://pmj.bmj.com/ race, formerly named Entamoeba histolytica minuta, gelatin capsules and the adult patient is given a is now named Entamoeba hartmanni. It produces course of 3 gr. (i8o mg.) each night for ten nights. cysts of mean diameter Io0± or less. This The drug causes gastric irritation with nausea and parasite is not believed to be pathogenic. Ridley vomiting, and colonic irritation with diarrhoea. and Schofield5 reported a study of the symptoms To diminish the former the patient is given a meal related to infection with it and showed no correla- at 6 p.m. and then no more food or drink until tion with symptoms of dysentery. The large race next morning. At 9 p.m. he is given a rapidly- on September 29, 2021 by guest. parasite Entamoeba histolytica produces cysts of acting sedative of which soluble phenobarbitone mean diameter about 2OtL. It may be a non- gr. i (6o mg.) by subcutaneous injection is pathogenic commensal, as is probably the case with suitable; and at io p.m. he is given the capsule those harbouring it in non-tropical environments. containing EBI. It is common for the patient to On the other hand some strains are virulent patho- awaken at about 2 a.m. feeling nauseated and he gens, ingesting red cells, invading the tissues, and may retch or vomit a little gastric juice containing causing amoebic dysentery and its complications. a few granules of the drug. If much of the dose is As yet, only detailed investigation by an experi- returned an additional dose is given at the end of enced worker, using three-week-old weanling rats the normal course. This gastric irritation often as experimental animals, will reveal differences in diminishes after the first few nights. It is pathogenicity of various strains of the large race probable that confining the patient to bed with parasites.4 only the use of the bathroom and toilet helps to 639 October I960 BELL: The Treatment of Amoebic Dysentery Postgrad Med J: first published as 10.1136/pgmj.36.420.638 on 1 October 1960. Downloaded from lessen the trouble. The diarrhoea due to EBI sold under the name Furamide, Boots Pure Drug commonly begins after about five or six days on Co. Ltd.). Details are reported by Woodruff and treatment. It is most important to recognize that Bell7 and a field trial in a tropical area is reported this is a side-effect of the drug, and not to regard by Marsden.3 This drug has given very good it as an indication for prolonged treatment. Some results in the radical cure of cyst passers and apart alleviation can be obtained by the use of a simple from some flatulence there have been no side- kaolin mixture and the patient should be assured effects. It is possible that this drug may prove that the diarrhoea will abate when the drug is suitable as a replacement for EBI for use in acute stopped. dysentery after symptoms have been controlled In the course of trials of many new drugs none by the use of emetine hydrochloride, for use ir~ has been found as yet which results in a higher cure treating cyst passers as out-patients, and for use in rate than EBI when properly administered.6 repeated courses for food-handlers in catering establishments in tropical and sub-tropical areas. Carriers of Amoebic Infection The drug is supplied in tablets each of 0.5 g. and Whether or not to treat those excreting cysts who the dose has been calculated on the basis of 20 mg. have no dysenteric symptoms depends on the per kg. body weight per day for ten days. history of the patient's condition. If he has suffered from bowel trouble and particularly if Treatment of Hepatic Complications of he has come from a tropical or subtropical area, Amoebic Infection and if the mean diameter of the cysts is greater Apart from aspiration of an abscess in the liver, than io li, it is wise to give treatment. EBI which is more successful and safer than open without preliminary emetine injections is most operation and drainage (except in the uncommon likely to cure the patient. case of an abscess in the left lobe), the treatment Trials with many other drugs have been made of hepatic amoebiasis is with emetine hydro- in the hope of finding one as effective but without chloride by subcutaneous injection in a dose of Protected by copyright. the. side-effects of EBI. i gr. (6o mg.) daily for ten days; or with chloro- Among the antibiotics tried are fumagillin and quine diphosphate or sulphate by mouth in a dose paromycin (Humatin, Parke Davis & Co.). The of 300 mg. of base thrice daily for two days and record of a trial of fumagillin was included in the then I50 mg. of base thrice daily for at least I2 report by Woodruff et al.6 Of 31 patients days. Where the parasites are present in the excreting cysts 27 had follow-up examinations bowel contents treatment with one of the drugs after treatment and one relapsed. Of three already mentioned is also required. Chloroquine who had trophozoites in their bowel contents, has no appreciable effect on these. two did not respond to the drug. Indigestion and desquamation of skin especially on the hands A trial with Humatin was REFERENCES were toxic effects. I. BELL, S., and WOODRUFF, A. W. (I960), Amer. J. trop. Med. reported by Bell and Woodruff.' Twenty patients 9 155. who were excreting cysts were treated and I9 were 2. HOARE, C. A. (I958), Rice Institute Pamphlet, 45, 27. 3. MARSDEN, P. D. (I960), Trans. roy. Soc. trop. Med. Hyg. http://pmj.bmj.com/ followed-up for periods ranging from one month 54, 396. to over one year with one relapse. Diarrhoea 4. NEAL, R. A. (1951), Ibid,. 44, 439. was a side-effect of this drug. S. RIDLEY, D. S., and SCHOFIELD, F. D. (I957), Ibid., si, 5I8. 6. WOODRUFF, A. W., BELL, S., and SCHOFIELD, F. D. The most promising of the newer synthetic (I956), Ibid., 50, I14. compounds has been Entamide furoate (now being 7. WOODRUFF, A.- WV., and BELL, S. (I960), Ibid., 54,389. on September 29, 2021 by guest..
Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N
    RESEARCH ARTICLE Identification of Candidate Agents Active against N. ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N. ceranae Infected Cultured Cells Sebastian Gisder, Elke Genersch* Institute for Bee Research, Department of Molecular Microbiology and Bee Diseases, Hohen Neuendorf, Germany * [email protected] Abstract OPEN ACCESS Many flowering plants in both natural ecosytems and agriculture are dependent on insect Citation: Gisder S, Genersch E (2015) Identification of Candidate Agents Active against N. ceranae pollination for fruit set and seed production. Managed honey bees (Apis mellifera) and wild Infection in Honey Bees: Establishment of a Medium bees are key pollinators providing this indispensable eco- and agrosystem service. Like all Throughput Screening Assay Based on N. ceranae other organisms, bees are attacked by numerous pathogens and parasites. Nosema apis is Infected Cultured Cells. PLoS ONE 10(2): e0117200. a honey bee pathogenic microsporidium which is widely distributed in honey bee popula- doi:10.1371/journal.pone.0117200 tions without causing much harm. Its congener Nosema ceranae was originally described Academic Editor: Wolfgang Blenau, Goethe as pathogen of the Eastern honey bee (Apis cerana) but jumped host from A. cerana to A. University Frankfurt, GERMANY mellifera about 20 years ago and spilled over from A. mellifera to Bombus spp. quite recent- Received: October 8, 2014 ly. N. ceranae is now considered a deadly emerging parasite of both Western honey bees Accepted: December 20, 2014 and bumblebees. Hence, novel and sustainable treatment strategies against N. ceranae are Published: February 6, 2015 urgently needed to protect honey and wild bees.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • ESCMID Online Lecture Library © by Author ESCMID Online Lecture Library
    Microsporidia, Dientamoeba and Blastocystis. © by author Tom van Gool Section Parasitology, AcademicESCMID Medical Online Centre, Amsterdam,Lecture NetherlandsLibrary Microsporidiosis in HIV-infected and HIV-negative individuals © by author ESCMID Online Lecture Library 1985: Mr. P. Bieneusi in Paris with AIDS ….in a biopsy of the small intestine a strange microorganism was observed with EM…… © by author ESCMID Online Lecture Library Prof. Isabelle Desportes Hôpital Pitié-Salpêtrière (Paris) © by author ESCMID Online Lecture Library “Small parasite belonging to the microsporidia but is unknown species”: Enterocytozoon bieneusi Microsporidia • obligate intracellular protozoan parasites • more than 144 genera and 1200 species • important parasites© by author in all phyla of animals ESCMID Online Lecture Library • since 1985 recognized in AIDS • nowadays 9 genera and 14 species Typical spore stage of microsporidia Coiled polar filament © by author ESCMID Online LectureThick Library exopspore with chitin Life cycle of microsporidia (Encephalitozoon) E.i. © by author ESCMID Online Lecture Library E.h. Schottelius MI 2000 Important microsporidia in AIDS I • Enterocytozoon bieneusi • Discovered in 1985 • Named after© byMr author Bieneusi • Most important microsporidian in ESCMIDAIDS Online Lecture Library The Lancet, Clinical Practice, 1991 • chronic diarrhea • cholangiopathy • rhinosinusitis© by author ESCMID• HIV infectedOnline patients Lecture CD 4Library <100 Diagnosis of Enterocytozoon bieneusi © by author ESCMID Online Lecture Library Diagnosis of human microsporidiosis 1985: electron microscopy of duodenal biopsies © by author ESCMID Online Lecture Library Drawback of all earlier methods of diagnosis: invasive procedure (small intestinal biopsy) needed Wanted: easy, non-invasive diagnostic procedure © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library E. bieneusi with Uvitex 2B stain © by author ESCMID Online Lecture Library E.
    [Show full text]
  • Infectious Keratitis: Short Answers
    Q Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? A Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? Pseudomonas Infectious keratitis: Short answers Pseudomonas corneal ulcer associated with CL wear Q Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? Pseudomonas What is the #1 risk factor for Acanthamoeba keratitis? A Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? Pseudomonas What is the #1 risk factor for Acanthamoeba keratitis? CL wear Infectious keratitis: Short answers Acanthamoeba keratitis associated with CL wear Q Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? Pseudomonas What is the #1 risk factor for Acanthamoeba keratitis? CL wear What are the three main culprits in fungal keratitis? What is the topical antifungal of choice for each? Fusarium:fungus 1 Topical…natamycin Aspergillisfungus 2 and Candida:fungus 3 A Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? Pseudomonas What is the #1 risk factor for Acanthamoeba keratitis? CL wear What are the three main culprits in fungal keratitis? What is the topical antifungal of choice for each? Candida: Topical…natamycin Aspergillis and Fusarium: Q Infectious keratitis: Short answers What is the #1 bacterium in CL-related K ulcer? Pseudomonas What is the #1 risk factor for Acanthamoeba keratitis? CL wear What are the three main culprits in fungal keratitis?
    [Show full text]
  • The Medical Letter
    Page 1 of 2 MICROSPORIDIOSIS Drug Adult dosage Pediatric dosage Ocular (Encephalitozoon hellem, E.cuniculi, Vittaforma corneae [Nosema corneum]) Drug of choice: Albendazole1,2 400 mg PO bid plus fumagillin3* Intestinal (E. bieneusi, E. [Septata] intestinalis) E. bieneusi Drug of choice: Fumagillin4* 20 mg PO tid x 14d E. intestinalis Drug of choice: Albendazole1,2 400 mg PO bid x 21d Disseminated (E. hellem, E. cuniculi, E. intestinalis, Pleistophora sp., Trachipleistophora sp. and Brachiola vesicularum) Drug of choice:5 Albendazole1,2* 400 mg PO bid * Availability problems. See table below. 1. Not FDA-approved for this indication. 2. Albendazole must be taken with food; a fatty meal increases oral bioavailability. 3. CM Chan et al, Ophthalmology 2003; 110:1420. Ocular lesions due to E. hellem in HIV-infected patients have responded to fumagillin eyedrops prepared from Fumidil-B (bicyclohexyl ammonium fumagillin) used to control a microsporidial disease of honey bees (MJ Garvey et al, Ann Pharmacother 1995; 29:872), available from Leiter’s Park Avenue Pharmacy, San Jose, CA (800-292-6773; www.leit- errx.com) is a compounding pharmacy that specializes in ophthalmic drugs. For lesions due to V. corneae, topical therapy is gener- ally not effective and keratoplasty may be required (RM Davis et al, Ophthalmology 1990; 97:953). 4. Oral fumagillin (Flisint – Sanofi-Aventis, France) has been effective in treating E. bieneusi (J-M Molina et al, N Engl J Med 2002; 346:1963), but has been associated with thrombocytopenia and neutropenia. Highly active antiretroviral therapy (HAART) may lead to microbiologic and clinical response in HIV-infected patients with microsporidial diarrhea.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Guidelines for Atcvet Classification 2012
    Guidelines for ATCvet classification 2012 ISSN 1020-9891 ISBN 978-82-8082-479-0 Suggested citation: WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATCvet classification 2012. Oslo, 2012. © Copyright WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. Guidelines for ATCvet classification 14th edition WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Norway Telephone: +47 21078160 Telefax: +47 21078146 E-mail: [email protected] Website: www.whocc.no Previous editions: 1992: Guidelines on ATCvet classification, 1st edition1) 1995: Guidelines on ATCvet classification, 2nd edition1) 1999: Guidelines on ATCvet classification, 3rd edition1) 2002: Guidelines for ATCvet classification, 4th edition2) 2003: Guidelines for ATCvet classification, 5th edition2) 2004: Guidelines for ATCvet classification, 6th edition2) 2005: Guidelines for ATCvet classification, 7th edition2) 2006: Guidelines for ATCvet classification, 8th edition2) 2007: Guidelines for ATCvet classification, 9th edition2) 2008: Guidelines for ATCvet classification, 10th edition2) 2009: Guidelines for ATCvet classification, 11th edition2) 2010: Guidelines for ATCvet classification, 12th edition2) 2011: Guidelines for ATCvet classification, 13th edition2) 1) Published by the Nordic Council on Medicines 2) Published by the WHO Collaborating Centre for Drug Statistics Methodology Preface The Anatomical Therapeutic Chemical classification system for veterinary medicinal products, ATCvet, has been developed by the Nordic Council on Medicines (NLN) in collaboration with the NLN’s ATCvet working group, consisting of experts from the Nordic countries.
    [Show full text]
  • Corneal Infections from A-Z Disclosures (Acanthamoeba to Zoster) Allergan Pharmaceutical Advisory Panel Joseph P
    8/28/16 Corneal Infections from A-Z Disclosures (Acanthamoeba to Zoster) Allergan Pharmaceutical Advisory Panel Joseph P. Shovlin, OD, FAAO AMO Global Medical Advisory Panel Scranton, PA -Acanthamoeba Outbreak Panel (ad hoc) Bausch & Lomb Scientific Advisory Panel -Global Steering Committee I. Risk Factors In Ulcerative Keratitis -Panel On Fusarium Keratitis (ad hoc) II. Differential Diagnosis of Infiltrative Keratitis Ciba Vision Post-Market Surveillance Study Group -Johns Hopkins Adjudication Committee (ad hoc) III. Treatment and Management of Ulcerative Keratitis Center for Disease Control & Prevention- Contact Lens Advisory Panel IV. Fungal and Protozoan Infection of the Johnson & Johnson Global Professional Advisory Panel Cornea Shire, Ophthalmic Advisory Panel Speaker’s Bureau: Vistakon, Ciba Vision, CooperVision, Bausch & Lomb, AMO, Alcon, V. The Herpes Family Genzyme, Shire 1 8/28/16 “Swine Flu”: H1N1 Infectious Keratitis Amoebic Herpes Keratitis Fungal Bacterial Keratitis Keratitis Keratitis 2 8/28/16 Case 7 -- corneal haze Stem Cell Deficiency Tear Film Defenses 3 8/28/16 Epidemiology: Relative Risk Risk Factors for Ulcerative Keratitis ¤ Population at risk: approximately 44 million in US and 120 million worldwide ¤Exogenous ¤ Overnight wear the overwhelming risk factor ¤Ocular Adnexal Dysfunction ¤ Relative risk of extended wear v. daily wear: 10- ¤Corneal Abnormalities 15:1 ¤Systemic Disease ¤ Overnight wear of disposable lenses equal risk ¤ Additional risks: aphakia, smoking, lens case, ¤Immunosuppressive Therapy minimal protective effect of hygiene Incidence Rates for Microbial Keratitis Microbial Keratitis Rates for Orthokeratology/Corneal Reshaping Any MK Severe MK ¤ Daily Wear GP 1.2 (1.1-1.5), 1.2 ¤ Incidence for microbial keratitis is estimated @ 7.7/10,000 ¤ Daily Wear DDCL 2.0 (1.7-2.4), .5 ¤ Children carry a higher rate @ 13.9/10,000 ¤ Overall, the infection rate is similar to overnight soft lens ¤ Occasional CW 2.2 (2.0-2.5), 1.8 use.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • Evaluation of Fumagilin-B® and Other Potential Alternative Chemotherapies Against Nosema Ceranae-Infected Honeybees (Apis Mellifera) in Cage Trial Assays Johan P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archive Ouverte en Sciences de l'Information et de la Communication Evaluation of Fumagilin-B® and other potential alternative chemotherapies against Nosema ceranae-infected honeybees (Apis mellifera) in cage trial assays Johan P. van den Heever, Thomas S. Thompson, Simon J. G. Otto, Jonathan M. Curtis, Abdullah Ibrahim, Stephen F. Pernal To cite this version: Johan P. van den Heever, Thomas S. Thompson, Simon J. G. Otto, Jonathan M. Curtis, Abdullah Ibrahim, et al.. Evaluation of Fumagilin-B® and other potential alternative chemotherapies against Nosema ceranae-infected honeybees (Apis mellifera) in cage trial assays. Apidologie, Springer Verlag, 2016, 47 (5), pp.617-630. 10.1007/s13592-015-0409-3. hal-01532347 HAL Id: hal-01532347 https://hal.archives-ouvertes.fr/hal-01532347 Submitted on 2 Jun 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Apidologie (2016) 47:617–630 Original article * INRA, DIB and Springer-Verlag France, 2015 DOI: 10.1007/s13592-015-0409-3 Evaluation of Fumagilin-B® and other potential alternative chemotherapies against Nosema ceranae -infected honeybees (Apis mellifera ) in cage trial assays 1 1 1,2 Johan P.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]